Alpha 2 macroglobuline immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-ActiTest®;Dosage immunoturbidimétrique de l'alpha 2 macroglobuline (réactifs DakoCytomation) sur les automates Roche Diagnostics (Modujar P, Cobas Intégra). Application au FibroTest-ActiTest®

Annales de Biologie Clinique

Volumn 63, Issue 4, 2005, Pages 385-395

  Piton, A ^a   Messous, D ^a   Imbert Bismut, F ^a   Berges J ^b   Munteanu, M ^a   Poynard, T ^a   Hainque, B ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Hôpital de la Salpêtière ^*  (France)

Author keywords

Alpha 2 macroglobuline; FibroTest ActiTesf ; Results transferability

Indexed keywords

ALPHA 2 MACROGLOBULIN;

ARTICLE; AUTOMATION; CLINICAL CHEMISTRY; HUMAN; IMMUNOASSAY; METHODOLOGY; PHOTOMETRY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ALPHA-MACROGLOBULINS; AUTOMATION; CLINICAL CHEMISTRY TESTS; HUMANS; IMMUNOASSAY; NEPHELOMETRY AND TURBIDIMETRY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 23644442926     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection : a prospective study. Lancet 2001 ; 357 : 1069-75.
2. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest®, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004 ; 3 : 8.
3. Myers PR, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003 ; 39 : 222-30.
4. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005 ; 3 : 167-74.
5. Ratziu V, Lecalvez S, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (Fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Hepatology 2003 ; 38 : 112A (abstract).
6. The French Metavir Co-operative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with renal chronic hepatitis C. Hepatology 1994 ; 20: 15-20.
7. Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of inter-laboratory variability of biochemical fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002 ; 1 : 3.
8. Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004 ; 42 : 323-33.
9. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurement from two different analytical methods. J Clin Chem Clin Biochem 1983 ; 21: 709-20.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 ; 1 : 307-10.
11. Marquis P. Method valuator Software. Metz, France, 1999.
12. Vassault A, Grafmeyer D, de Graeve J, Cohen R, Beaudonnet A, Bienvenu J. Analyses de biologie médicale : spécifications et normes d'acceptabilité à l'usage de la validation de techniques. Ann Biol Clin 1999 ; 57 : 685-95.
13. Hintze JL. Number cruncher statistical systems. Software NCSS. Kaysville : Uthah, 2003.
14. Schuman G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med 2002 ; 40 : 718-24.
15. Szasz G, Persijn JP, Van der Slik WA. A new method for the determination of gamma -glutamyl transferase. J Clin Chem Clin Biochem 1976 ; 14 : 421-7.
16. Wahefeld AW, Herz G, Bernt E. Modification of the Malloy-Evelyn method for a simple, reliable determination of total bilirubin in serum. Scand J Clin Lab Invest 1972 ; 29 : 11-2.
17. Doumas BT, Perry BN, Sasse EA, Straumfjord JR. Standardisation in bilirubin assays : evaluation of selected methods and stability of bilirubin solutions. Clin Chem 1973 ; 19 : 984-93.
18. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004 ; 50 : 1344-55.
19. Baudner S, Bienvenu J, Blirup-Jensen J, et al. In : The certification of a matrix reference materiel for immunochemical measurement of 14 human serum proteins. CRM 470. Bruxelles : Community Bureau of Reference, Commision of European Communities, 1993 : 1-172.
20. Johnson AM, Whicher JT. Effect of certified reference material 470 (CRM 470) on national quality assurance programs for serum proteins in europe. Clin Chem Lab Med 2001 ; 39 : 1123-8.
21. Directive 98/79/CE du parlement européen et du conseil du 27 octobre 1998, relative aux « dispositifs médicaux de diagnostic in vivo ». Journal officiel des Communautés européennes 7.12.98, L. 331-3.